<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39000027</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>13</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Assessing the Potential of an Enzymatically Liberated Salmon Oil to Support Immune Health Recovery from Acute SARS-CoV-2 Infection via Change in the Expression of Cytokine, Chemokine and Interferon-Related Genes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6917</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25136917</ELocationID><Abstract><AbstractText>Cytokines, chemokines, and interferons are released in response to viral infection with the ultimate aim of viral clearance. However, in SARS-CoV-2 infection, there is an imbalanced immune response, with raised cytokine levels but only a limited interferon response with inefficient viral clearance. Furthermore, the inflammatory response can be exaggerated, which risks both acute and chronic sequelae. Several observational studies have suggested a reduced risk of progression to severe COVID-19 in subjects with a higher omega-3 index. However, randomized studies of omega-3 supplementation have failed to replicate this benefit. Omega-3 fats provide important anti-inflammatory effects; however, fatty fish contains many other fatty acids that provide health benefits distinct from omega-3. Therefore, the immune health benefit of whole salmon oil (SO) was assessed in adults with mild to moderate COVID-19. Eleven subjects were randomized to best supportive care (BSC) with or without a full spectrum, enzymatically liberated SO, dosed at 4g daily, for twenty-eight days. Nasal swabs were taken to measure the change in gene expression of markers of immune response and showed that the SO provided both broad inflammation-resolving effects and improved interferon response. The results also suggest improved lung barrier function and enhanced immune memory, although the clinical relevance needs to be assessed in longer-duration studies. In conclusion, the salmon oil was well tolerated and provided broad inflammation-resolving effects, indicating a potential to enhance immune health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Currie</LastName><ForeName>Crawford</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4441-5262</Identifier><AffiliationInfo><Affiliation>Hofseth BioCare, Keiser Wilhelms Gate 24, 6003 Alesund, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myklebust</LastName><ForeName>Tor &#xc5;ge</ForeName><Initials>T&#xc5;</Initials><AffiliationInfo><Affiliation>Department of Research and Innovation, More og Romsdal Hospital Trust, 6026 &#xc5;lesund, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Registration, Cancer Registry of Norway, 0379 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjerknes</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hofseth BioCare, Keiser Wilhelms Gate 24, 6003 Alesund, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Framroze</LastName><ForeName>Bomi</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5251-8982</Identifier><AffiliationInfo><Affiliation>Hofseth BioCare, Keiser Wilhelms Gate 24, 6003 Alesund, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20CCHH/OP110921</GrantID><Agency>Hofseth BioCare</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005395">Fish Oils</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>68991-43-5</RegistryNumber><NameOfSubstance UI="C030341">salmon oil</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005395" MajorTopicYN="Y">Fish Oils</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="Y">Interferons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="Y">Chemokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">chemokine</Keyword><Keyword MajorTopicYN="N">cytokine</Keyword><Keyword MajorTopicYN="N">gene expression</Keyword><Keyword MajorTopicYN="N">immune health</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">lipid mediators</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>C.C., C.B., and B.F. are employees or consultants for Hofseth BioCare ASA, the sponsor of this study. T.&#xc5;.M. collaborates with Hofseth BioCare ASA to support statistical planning and analysis and is paid for this on an ad hoc basis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>13</Day><Hour>7</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>13</Day><Hour>7</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>13</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39000027</ArticleId><ArticleId IdType="pmc">PMC11241394</ArticleId><ArticleId IdType="doi">10.3390/ijms25136917</ArticleId><ArticleId IdType="pii">ijms25136917</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Queiroz M.A.F., Moura da Neves P.F., Lima S.S., Lopes J.D.C., Torres M.K.D.S., Vallinoto I.M.V.C., Bichara C.D.A., Santos E.F.D., de Brito M.T.F.M., da Silva A.L.S., et al. Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome. Front. Cell Infect. Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Scultheis C., Wilscher E., Paschold L., Gottschick C., Klee B., Henkes S.S., Bosurgi L., Dutzmann J., Sedding D., Frese T., et al. The IL-1, IL-6 and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 2022;6:100663. doi: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudowska-Sawczuk M., Mroczko B. What is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection? Int. J. Mol. Sci. 2022;7:3673. doi: 10.3390/ijms23073673.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23073673</ArticleId><ArticleId IdType="pmc">PMC8998241</ArticleId><ArticleId IdType="pubmed">35409036</ArticleId></ArticleIdList></Reference><Reference><Citation>Unterman A., Sumida T.S., Nouri N., Yan X., Zhao A.Y., Gasque V., Schupp J.C., Asashima H., Liu Y., Cosme C., Jr., et al. Single cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nat. Commun. 2022;13:440. doi: 10.1038/s41467-021-27716-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27716-4</ArticleId><ArticleId IdType="pmc">PMC8782894</ArticleId><ArticleId IdType="pubmed">35064122</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Li Y., Liu Q., Yao Q., Wang X., Zhang H., Chen R., Ren L., Min J., Deng F., et al. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov. 2021;1:17. doi: 10.1038/s41421-021-00249-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00249-2</ArticleId><ArticleId IdType="pmc">PMC7987126</ArticleId><ArticleId IdType="pubmed">33758165</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhardt N., Noval M.G., Kaur R., Amadori L., Gildea M., Sajja S., Das D., Cilhoroz B., Stewart O.J., Fernandez D.M., et al. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. Nat. Cardiovasc. Res. 2023;2:889&#x2013;916. doi: 10.1038/s44161-023-00336-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44161-023-00336-5</ArticleId><ArticleId IdType="pmc">PMC10702930</ArticleId><ArticleId IdType="pubmed">38076343</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Meol D., Nilsson-Payant E., Liu W.C., Uhl S., Hoagland D., M&#xf8;ller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;5:1036&#x2013;1045. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Janeway C.A., Medzihitov R. Innate Immune Recognition. Ann. Rev. Immunol. 2002;20:197&#x2013;216. doi: 10.1146/annurev.immunol.20.083001.084359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.20.083001.084359</ArticleId><ArticleId IdType="pubmed">11861602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaer H.M., Schoggins J.W., Diamond M.S. Shared and Distinct Functions of Type I and III Interferons. Immunity. 2019;4:907&#x2013;923. doi: 10.1016/j.immuni.2019.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.025</ArticleId><ArticleId IdType="pmc">PMC6839410</ArticleId><ArticleId IdType="pubmed">30995506</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008;9:503&#x2013;510. doi: 10.1038/ni1582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1582</ArticleId><ArticleId IdType="pubmed">18425107</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkowski M., Tizian C., Ferreira-Gomes M., Niemeyer D., Jones T.C., Heinrich F., Frischbutter S., Angermair S., Hohnstein T., Mattiola I., et al. Untimely TGF&#x3b2; responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021;600:295&#x2013;300. doi: 10.1038/s41586-021-04142-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04142-6</ArticleId><ArticleId IdType="pubmed">34695836</ArticleId></ArticleIdList></Reference><Reference><Citation>Terjerina F., Catalan P., Rodriguez-Grande C., Adan J., Rodriguez-Gonzalez C., Mu&#xf1;oz P., Aldamiz T., Diez C., Perez L., Fanciulli C., et al. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect. Dis. 2022;22:211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Blish C.A., Sallusto F., Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122&#x2013;1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris W.S., Tintle N.L., Sathyanarayanan S.P., Westra J. Association between blood N-3 fatty acid levels and the risk of coronavirus disease 2019 in the UK Biobank. Am. J. Clin. Nutr. 2023;117:357&#x2013;363. doi: 10.1016/j.ajcnut.2022.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajcnut.2022.11.011</ArticleId><ArticleId IdType="pmc">PMC9972865</ArticleId><ArticleId IdType="pubmed">36863828</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang N., Serhan C.N. Specialized pro-resolving mediator network: An update on production and actions. Essays Biochem. 2020;3:443&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682745</ArticleId><ArticleId IdType="pubmed">32885825</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.S., Sun H.L., Lii C.K., Chen H.W., Chen P.Y., Liu K.L. Gamma-linolenic acid inhibits inflammatory responses by regulating NF-kappaB and AP-1 activation in lipopolysaccharide-induced RAW 264.7 macrophages. Inflammation. 2010;1:46&#x2013;57. doi: 10.1007/s10753-009-9157-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-009-9157-8</ArticleId><ArticleId IdType="pubmed">19842026</ArticleId></ArticleIdList></Reference><Reference><Citation>De Souza C.O., Valenzuela C.A., Baker E.J., Miles E.A., Rosa Neto J.C., Calder P.C. Palmitoleic acid has stronger anti-inflammatory potential in human endothelial cells compared to oleic and palmitic acids. Mol. Nutr. Food Res. 2018;20:e1800322. doi: 10.1002/mnfr.201800322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.201800322</ArticleId><ArticleId IdType="pubmed">30102465</ArticleId></ArticleIdList></Reference><Reference><Citation>Venn-Watson S., Lumpkin R., Dennis E.A. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: Could it be essential? Sci. Rep. 2020;10:8161. doi: 10.1038/s41598-020-64960-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-64960-y</ArticleId><ArticleId IdType="pmc">PMC7235264</ArticleId><ArticleId IdType="pubmed">32424181</ArticleId></ArticleIdList></Reference><Reference><Citation>Framroze B., Heggdal H. An in vitro study to explore the modulation of eosinophil effector function in human allergic peripheral blood eosinophils using enzymatically extracted salmonid oil. Funct. Foods Health Dis. 2020;10:357. doi: 10.31989/ffhd.v10i8.730.</Citation><ArticleIdList><ArticleId IdType="doi">10.31989/ffhd.v10i8.730</ArticleId></ArticleIdList></Reference><Reference><Citation>Frediani J.K., Parsons R., McLendon K.B., Westbrook A.L., Lam W., Martin G., Pollock N.R. The New Normal: Delayed Peak SARS-CoV-2 Viral Loads Relative to Symptom Onset and Implications for COVID-19 Testing Programs. Clin. Infect Dis. 2024;78:301&#x2013;307. doi: 10.1093/cid/ciad582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad582</ArticleId><ArticleId IdType="pmc">PMC10874267</ArticleId><ArticleId IdType="pubmed">37768707</ArticleId></ArticleIdList></Reference><Reference><Citation>Faes C., Abrams S., van Beckhoven D., Meyfroidt G., Vlieghe E., Hens N., Belgian Collaborative Group on COVID-19 Hospital Surveillance Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients. Int. J. Environ. Res. Public Health. 2020;17:7560. doi: 10.3390/ijerph17207560.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17207560</ArticleId><ArticleId IdType="pmc">PMC7589278</ArticleId><ArticleId IdType="pubmed">33080869</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Guo L., Yuan J., Xu Z., Gu Y., Zhang J., Guan Y., Liang J., Lu H., Liu Y. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): A prospective cohort study from Shezhen, China. Lancet. 2023;4:e632&#x2013;e641. doi: 10.1016/S2666-5247(23)00139-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00139-8</ArticleId><ArticleId IdType="pubmed">37459867</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M.C., Bonham K.S., Anam F.A., Walker T.A., Faliti C.E., Ishii Y., Kaminski C.Y., Ruunstrom M.C., Cooper K.R., Truong A.D., et al. Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID. Nat. Commun. 2023;14:4201. doi: 10.1038/s41467-023-40012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40012-7</ArticleId><ArticleId IdType="pmc">PMC10349085</ArticleId><ArticleId IdType="pubmed">37452024</ArticleId></ArticleIdList></Reference><Reference><Citation>Donlan A.N., Sutherland T.E., Marie C., Preissner S., Bradley B.T., Carpenter R.M., Sturek J.M., Ma J.Z., Moreau G.B., Donowitz J.R., et al. IL-13 is a driver of COVID-19 severity. JCI Insight. 2021;15:e150107. doi: 10.1172/jci.insight.150107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.150107</ArticleId><ArticleId IdType="pmc">PMC8410056</ArticleId><ArticleId IdType="pubmed">34185704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A., Vecchie A., Wang T.S., Lee E., Cremer P.C., Carey B., Rajendram P., Hudock K.M., Korbee L., Van Tassell B.W., et al. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front. Immunol. 2020;11:01625. doi: 10.3389/fimmu.2020.01625.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01625</ArticleId><ArticleId IdType="pmc">PMC7348297</ArticleId><ArticleId IdType="pubmed">32719685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.M., Kim Y., Seo J.W., Lee J., Park U., Ha N.Y., Koh J., Park H., Lee J.W., Ro H.J., et al. Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19. Cell. Rep. 2021;1:109798. doi: 10.1016/j.celrep.2021.109798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109798</ArticleId><ArticleId IdType="pmc">PMC8450316</ArticleId><ArticleId IdType="pubmed">34587481</ArticleId></ArticleIdList></Reference><Reference><Citation>Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., Holloway A.J., Johnstone R.W. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA. 2005;102:3697&#x2013;3702. doi: 10.1073/pnas.0500369102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0500369102</ArticleId><ArticleId IdType="pmc">PMC552783</ArticleId><ArticleId IdType="pubmed">15738394</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy D.J., Smyth G.K. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics. 2009;6:765&#x2013;771. doi: 10.1093/bioinformatics/btp053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp053</ArticleId><ArticleId IdType="pmc">PMC2654802</ArticleId><ArticleId IdType="pubmed">19176553</ArticleId></ArticleIdList></Reference><Reference><Citation>Cperchini F., Chiovato L., Rotondo M. Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One! Front. Immunol. 2021;12:668507. doi: 10.3389/fimmu.2021.668507.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.668507</ArticleId><ArticleId IdType="pmc">PMC8107352</ArticleId><ArticleId IdType="pubmed">33981314</ArticleId></ArticleIdList></Reference><Reference><Citation>Noto A., Joo V., Mancarella A., Suffiotti M., Pellaton C., Fenwick C., Perreau M., Pantaleo G. CXCL-12 and CXCL-13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses. Viruses. 2022;14:2665. doi: 10.3390/v14122665.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122665</ArticleId><ArticleId IdType="pmc">PMC9785906</ArticleId><ArticleId IdType="pubmed">36560669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozai M., Kubo Y., Katakai T., Kondo H., Kiyonari H., Schaeuble K., Luther S.A., Ishimaru N., Ohigashi I., Takahama Y. Essential role of CCL21 in establishment of central self-tolerance in T cells. J. Exp. Med. 2017;7:1925&#x2013;1935. doi: 10.1084/jem.20161864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20161864</ArticleId><ArticleId IdType="pmc">PMC5502431</ArticleId><ArticleId IdType="pubmed">28611158</ArticleId></ArticleIdList></Reference><Reference><Citation>Perreau M., Suffiotti M., Marques-Vidal P., Wiedemann A., Levy Y., Laou&#xe9;nan C., Ghosn J., Fenwick C., Comte D., Roger T., et al. The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nat. Commun. 2021;12:4888. doi: 10.1038/s41467-021-25191-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25191-5</ArticleId><ArticleId IdType="pmc">PMC8352963</ArticleId><ArticleId IdType="pubmed">34373466</ArticleId></ArticleIdList></Reference><Reference><Citation>Celik N., Celik O., Laloglu E., &#xd6;zkaya A. The CXCL9/10/11-CXCR3 axis as a predictor of COVID-19 progression: A prospective case-control study. Rev. Soc. Bras. Med. Trop. 2023;56:e0128&#x2013;e2023. doi: 10.1590/0037-8682-0128-2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0037-8682-0128-2023</ArticleId><ArticleId IdType="pmc">PMC10367208</ArticleId><ArticleId IdType="pubmed">37493737</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H., Cao Z., Xie X., Zhang X., Chen J.Y.C., Wang H., Menachery V.D., Rajsbaum R., Shi P.Y. Evasion of Type I Interferon by SARS-CoV-2. Cell. Rep. 2020;33:08234. doi: 10.1016/j.celrep.2020.108234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108234</ArticleId><ArticleId IdType="pmc">PMC7501843</ArticleId><ArticleId IdType="pubmed">32979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L., Ren L., et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun. 2020;1:3810. doi: 10.1038/s41467-020-17665-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17665-9</ArticleId><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Messurier K.S., H&#xe4;cker H., Chi L., Tuomanen E., Redecke V. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog. 2013;9:e1003727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820719</ArticleId><ArticleId IdType="pubmed">24244159</ArticleId></ArticleIdList></Reference><Reference><Citation>Odendall C., Voak A.A., Kagan J.C. Type III IFNs are commonly induced by bacteria-sensing TLRs and reinforce epithelial barriers during infection. J. Immunol. 2017;199:3270&#x2013;3279. doi: 10.4049/jimmunol.1700250.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1700250</ArticleId><ArticleId IdType="pmc">PMC5679450</ArticleId><ArticleId IdType="pubmed">28954888</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G., Moreira Silva E.A.S., Meideros Silva D.C., Thabane L., Campos V.H., Ferreira T.S., Santos C.V., Nogueira A.M., Almeida A.P., Savassi L.C., et al. Early treatment with pegylated interferon lambda for COVID-19. N. Engl. J. Med. 2023;388:518&#x2013;528. doi: 10.1056/NEJMoa2209760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2209760</ArticleId><ArticleId IdType="pmc">PMC9933926</ArticleId><ArticleId IdType="pubmed">36780676</ArticleId></ArticleIdList></Reference><Reference><Citation>Myasnikov A.L., Berns S.A., Talyzin P.A., Ershov F.I. Interferon gamma in the treatment of patients with moderate COVID-19. Vopr. Virusol. 2021;66:47&#x2013;54. doi: 10.36233/0507-4088-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.36233/0507-4088-24</ArticleId><ArticleId IdType="pubmed">33683065</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laarhoven A., Kurver L., Overheul G.J., Kooistra E.J., Abdo W.F., van Crevel R., Duivenvoorden R., Kox M., Oever J.T., Schouten J., et al. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series. Med. 2021;2:1163&#x2013;1170. doi: 10.1016/j.medj.2021.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.09.003</ArticleId><ArticleId IdType="pmc">PMC8452508</ArticleId><ArticleId IdType="pubmed">34568856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilligan K.L., Namasivayam S., Clancy C.S., Baker P.J., Old S.I., Peluf V., Amaral E.P., Oland S.D., O&#x2019;Mard D., Laux J., et al. Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2. Nat. Commun. 2023;14:8829. doi: 10.1038/s41467-023-43447-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43447-0</ArticleId><ArticleId IdType="pmc">PMC10716133</ArticleId><ArticleId IdType="pubmed">38086794</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins J.W. ISGs: What do they do? Ann. Rev. Virol. 2019;1:567&#x2013;584. doi: 10.1146/annurev-virology-092818-015756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-092818-015756</ArticleId><ArticleId IdType="pubmed">31283436</ArticleId></ArticleIdList></Reference><Reference><Citation>Vladimer G.I., Gorner M.W., Superti-Furga G. IFITS: Emerging roles as key antiviral proteins. Front. Immunol. 2014;5:94. doi: 10.3389/fimmu.2014.00094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00094</ArticleId><ArticleId IdType="pmc">PMC3948006</ArticleId><ArticleId IdType="pubmed">24653722</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda K., Takaoka A., Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006;25:349&#x2013;360. doi: 10.1016/j.immuni.2006.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.08.009</ArticleId><ArticleId IdType="pubmed">16979567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W., Huang G., Wang Z., Wang L., Gao Q. IRF7: Role and regulation in immunity and autoimmunity. Front. Immunol. 2023;14:1236923. doi: 10.3389/fimmu.2023.1236923.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1236923</ArticleId><ArticleId IdType="pmc">PMC10449649</ArticleId><ArticleId IdType="pubmed">37638030</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., et al. Irf-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005;7034:772&#x2013;777. doi: 10.1038/nature03464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03464</ArticleId><ArticleId IdType="pubmed">15800576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohnacker S., Hartung F., Henkel F., Quaranta A., Kolmert J., Priller A., Ud-Dean M., Giglberger J., Kugler L.M., Pechtold L., et al. Mild COVID-19 imprints a long-term inflammatory eicosanoid-and chemokine memory in monocyte-derived macrophages. Mucosal Immunol. 2022;15:515&#x2013;524. doi: 10.1038/s41385-021-00482-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-021-00482-8</ArticleId><ArticleId IdType="pmc">PMC9038526</ArticleId><ArticleId IdType="pubmed">35288643</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmas F., Clarke J., Colas R.A., Gomez E.A., Keogh A., Boylan M., McEvoy N., McElvaney O.J., McElvaney O., Alalqam R., et al. Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients. PLoS ONE. 2021;8:e0256226. doi: 10.1371/journal.pone.0256226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256226</ArticleId><ArticleId IdType="pmc">PMC8389414</ArticleId><ArticleId IdType="pubmed">34437568</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenis D.S., Beegun I., Jouvene C.C., Aguirre G.A., Souza P.R., Gonzalez-Nunez M., Ly L., Pistorius K., Kocher H.M., Ricketts W., et al. Disrupted Resolution Mechanisms Favor Altered Phagocyte Response in COVID-19. Circ. Res. 2021;129:e54&#x2013;e71. doi: 10.1161/CIRCRESAHA.121.319142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.319142</ArticleId><ArticleId IdType="pmc">PMC8336787</ArticleId><ArticleId IdType="pubmed">34238021</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M., Iwasaki A. The neurobiology of long COVID. Neuron. 2022;110:3484&#x2013;3496. doi: 10.1016/j.neuron.2022.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y.J., Liu S.H., Manachevakul S., Lee T.A., Kuo C.T., Bello D. Biomarkers in long COVID-19: A systematic review. Front. Med. 2023;10:1085988. doi: 10.3389/fmed.2023.1085988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1085988</ArticleId><ArticleId IdType="pmc">PMC9895110</ArticleId><ArticleId IdType="pubmed">36744129</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder P.C. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochem. Biophys. Acta. 2015;1851:469&#x2013;484. doi: 10.1016/j.bbalip.2014.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2014.08.010</ArticleId><ArticleId IdType="pubmed">25149823</ArticleId></ArticleIdList></Reference><Reference><Citation>Regidor P.-A., Mueller A., Sailer M., Gonzalez Santos F., Rizo J.M., Egea F.M. Chronic inflammation in PCOS: The potential benefits of specialized pro-resolving lipid mediators (SPMs) in the improvement of the resolutive response. Int. J. Mol. Sci. 2020;22:384. doi: 10.3390/ijms22010384.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22010384</ArticleId><ArticleId IdType="pmc">PMC7795660</ArticleId><ArticleId IdType="pubmed">33396555</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang N., Serhan C.N. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol. Aspects Med. 2017;58:114&#x2013;129. doi: 10.1016/j.mam.2017.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2017.03.005</ArticleId><ArticleId IdType="pmc">PMC5623601</ArticleId><ArticleId IdType="pubmed">28336292</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M., Kuba K., Ichikawa A., Nakayama M., Katahira J., Iwamoto R., Watanebe T., Sakabe S., Daidoji T., Nakamura S., et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell. 2013;1:112&#x2013;125. doi: 10.1016/j.cell.2013.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.02.027</ArticleId><ArticleId IdType="pubmed">23477864</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunvoll S.H., Nygaard B., Ellingjord-Dale M., Holland P., Istre M.S., Kalleberg K.T., S&#xf8;raas C.L., Holven K.B., Ulven S.M., Hjart&#xe5;ker A., et al. Prevention of COVID-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: Quadruple blinded, randomised placebo-controlled trial. BMJ. 2022;378:e071245. doi: 10.1136/bmj-2022-071245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-071245</ArticleId><ArticleId IdType="pmc">PMC9449357</ArticleId><ArticleId IdType="pubmed">36215222</ArticleId></ArticleIdList></Reference><Reference><Citation>Velotti F., Costantini L., Merendino N. Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) for Immunomodulation in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) J. Clin. Med. 2022;1:304. doi: 10.3390/jcm12010304.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12010304</ArticleId><ArticleId IdType="pmc">PMC9820910</ArticleId><ArticleId IdType="pubmed">36615103</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen T.V., Dalli J., Serhan C.N. The novel lipid mediator PD1n-3 DPA: An overview of the structural elucidation, synthesis, biosynthesis and bioactions. Prostaglandins. 2017;133:103&#x2013;110. doi: 10.1016/j.prostaglandins.2017.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prostaglandins.2017.06.003</ArticleId><ArticleId IdType="pmc">PMC5720935</ArticleId><ArticleId IdType="pubmed">28602942</ArticleId></ArticleIdList></Reference><Reference><Citation>Pistorius K., Souza P.R., De Matteis R., Austin-Williams S., Primdahl K.G., Vik A., Mazzacuva F., Colas R.A., Marques R.M., Hansen T.V., et al. PDn-3 DPA Pathway Regulates Human Monocyte Differentiation and Macrophage Function. Cell Chem. Biol. 2018;6:749&#x2013;760 e9. doi: 10.1016/j.chembiol.2018.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2018.04.017</ArticleId><ArticleId IdType="pmc">PMC6024030</ArticleId><ArticleId IdType="pubmed">29805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Droin G., Rioux V., Legrand P. The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family. Biochemie. 2019;159:36&#x2013;48. doi: 10.1016/j.biochi.2019.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2019.01.022</ArticleId><ArticleId IdType="pubmed">30716358</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Mar&#xed;a C., L&#xf3;pez-Enr&#xed;quez S., la Paz S.M.-D., Geniz I., Reyes-Quiroz M.E., Moreno M., Palomares F., Sobrino F., Alba G. Update on Anti-Inflammatory Molecular Mechanism Induced by Oleic Acid. Nutrients. 2023;1:224. doi: 10.3390/nu15010224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15010224</ArticleId><ArticleId IdType="pmc">PMC9824542</ArticleId><ArticleId IdType="pubmed">36615882</ArticleId></ArticleIdList></Reference><Reference><Citation>Venn-Watson S.K., Butterworth C.N. Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of emerging essential fatty acid across twelve primary human cell-based disease systems. PLoS ONE. 2022;5:e0268778. doi: 10.1371/journal.pone.0268778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268778</ArticleId><ArticleId IdType="pmc">PMC9135213</ArticleId><ArticleId IdType="pubmed">35617322</ArticleId></ArticleIdList></Reference><Reference><Citation>Deo P., Dhillon V.S., Thomas P., Fenech M. Oleic Acid Status Positively Correlates with the Soluble Receptor for Advanced Glycation End-Products (sRAGE) in Healthy Adults Who Are Homozygous for G Allele of RAGE G82S Polymorphism. Cells. 2023;12:1662. doi: 10.3390/cells12121662.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12121662</ArticleId><ArticleId IdType="pmc">PMC10297244</ArticleId><ArticleId IdType="pubmed">37371132</ArticleId></ArticleIdList></Reference><Reference><Citation>Holms R.D. Long COVID (PASC) Is Maintained by a Self-Sustaining Pro-Inflammatory TLR4/RAGE-Loop of S100A8/A9 &gt;TLR4/RAGE Signalling, Inducing Chronic Expression of IL-1b, IL-6 and TNFa: Anti-Inflammatory Ezrin Peptides as Potential Therapy. Immuno. 2022;2:512&#x2013;533. doi: 10.3390/immuno2030033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/immuno2030033</ArticleId></ArticleIdList></Reference><Reference><Citation>Currie C., Framroze B., Singh D., Sharma D., Bjerknes C., Hermansen E. Pharmacological evaluation of the effects of enzymatically liberated fish oil on eosinophilic inflammation in animal models. Biotechnol. Appl. Biochem. 2023;1:157&#x2013;163. doi: 10.1002/bab.2338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bab.2338</ArticleId><ArticleId IdType="pubmed">35353942</ArticleId></ArticleIdList></Reference><Reference><Citation>Currie C., Framroze B., Singh D., Lea S., Bjerknes C., Hermansen E. Assessing the Anti-Inflammatory Effects of an Orally Dosed Enzymatically Liberated Fish Oil in a House Dust Model of Allergic Asthma. Biomedicines. 2022;10:2574. doi: 10.3390/biomedicines10102574.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10102574</ArticleId><ArticleId IdType="pmc">PMC9599594</ArticleId><ArticleId IdType="pubmed">36289834</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Xiao P., Lei S., Deng F., Xiao G.G., Liu Y., Chen X., Li L., Wu S., Chen Y. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim. Biophys. Sin. 2008;40:426&#x2013;436. doi: 10.1111/j.1745-7270.2008.00418.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7270.2008.00418.x</ArticleId><ArticleId IdType="pubmed">18465028</ArticleId></ArticleIdList></Reference><Reference><Citation>Koussounadis A., Langdon S.P., Um I.H., Harrison D.J., Smith V.A. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft mouse model system. Sci. Rep. 2015;5:10775. doi: 10.1038/srep10775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep10775</ArticleId><ArticleId IdType="pmc">PMC4459080</ArticleId><ArticleId IdType="pubmed">26053859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlei M., Sidorov I.A., Joosten S.A., Heemskerk M.H.M., Myeni S.K., Pothast C.R., de Brouwer C.S., der Zanden A.L.B.-V., van Meijgaarden K.E., Morales S.T., et al. Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Na&#xef;ve CD4+ Cell Counts Correspond with Delayed Viral Clearance. Cells. 2022;11:2743. doi: 10.3390/cells11172743.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11172743</ArticleId><ArticleId IdType="pmc">PMC9455062</ArticleId><ArticleId IdType="pubmed">36078151</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>